Author: Ken Dropiewski

Adagio Medical Announces Positive Pivotal Results for vCLAS® Ventricular Ablation System

Rhythm by 0 comments

LAGUNA HILLS, Calif.–(BUSINESS WIRE)—- $ADGM #Arrhythmia–Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today reported six month results from its FULCRUM-VT Investigational Device Exemption (“IDE”) clinical trial, which will be used to support the Company’s application for Food and Drug Administration (“FDA”) Premarket Approval of the vCLAS Ventricular Ablation System. The results were prese

Continue Reading →

Guerbet announces an important milestone achievement in the “Vascular Embolization” indication for Lipiodol® Ultra Fluid (Iodinated ethyl esters of fatty acids of poppy seed oil)

Peripheral/Endo by 0 comments

VILLEPINTE, France, April 24, 2026 /PRNewswire/ — GUERBET (FR0000032526 GBT): Guerbet, a global leader in medical imaging, announces a positive outcome from a worksharing procedure, involving several EU member states, for a new Lipiodol® indication in interventional radiology procedures…

Continue Reading →

Edwards Lifesciences Reports First Quarter Results

Financial by 0 comments

IRVINE, Calif.–(BUSINESS WIRE)–Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended March 31, 2026. Highlights and Outlook Q1 sales grew 16.7% to $1.65 billion1, constant currency2 sales grew 12.7% Q1 TAVR sales grew 14.4% to $1.20 billion1; constant currency2 sales grew 11.0% Q1 TMTT sales of $173 million1,3, driven by repair and replacement therapies Q1 EPS of $0.661; adjusted2 EPS of $0.781 Raising FY 2026 constant currency2 sales growth guidance to 9% to

Continue Reading →

Anaxiom Announces Early Clinical Results from First-in-Human Experience of Novel Minimally Invasive Obesity Device; Advances Toward U.S. Early Feasibility Study

Coronary/Structural Heart by 0 comments

LAGUNA HILLS, Calif.–(BUSINESS WIRE)–Anaxiom Corporation, a clinical-stage medical device company developing a novel, non-surgical treatment for obesity, today announced the successful completion of a 12-patient OUS clinical study. Early results demonstrate device safety and promising weight loss supporting advancement toward a U.S. Early Feasibility Study. Promising Early Clinical Experience The […]

Continue Reading →

NEW STUDY LINKS GLP-1 MEDICATIONS TO LOWER RISK OF ATRIAL FIBRILLATION, INDEPENDENT OF WEIGHT LOSS

Rhythm by 0 comments

CHICAGO, IL, APRIL 23, 2026 – A new study analyzing data from more than 13,000 patients found that people using the increasingly popular weight-loss drugs known as GLP-1 receptor agonists (GLP-1-RAs) have a reduced risk of atrial fibrillation (AF), even after accounting for the medications’ effects on weight loss and overall […]

Continue Reading →

Late-Breaking Data from PRESERVE Trial Evaluates XVIVO’s HOPE Preservation Approach in Heart Transplantation

Coronary/Structural Heart by 0 comments

Preliminary results suggest potential to support extended preservation time and donor heart utilization TORONTO–(BUSINESS WIRE)–XVIVO, a global medtech company in the organ transplant industry, today announced late-breaking preliminary data from the PRESERVE Trial (NCT05881278) evaluating hypothermic oxygenated perfusion (HOPE) using the XVIVO Heart Assist Transport™. The trial met its pre-specified […]

Continue Reading →

APPLE WATCH CAPTURES MORE PEDIATRIC ARRHYTHMIA EVENTS THAN TRADITIONAL PATCH MONITORS

Rhythm by 0 comments

CHICAGO, IL, APRIL 25, 2026 – A new study examining the accuracy of wearable technologies for capturing irregular heartbeats in children found that the Apple Watchâ can capture arrhythmia events potentially more effectively than traditional ambulatory patch rhythm monitors. Researchers presented these findings as an oral abstract today at Heart Rhythm 2026. Arrhythmias occur […]

Continue Reading →

FLEX Vascular Announces 12-Month Real-World Outcomes Demonstrating Strong Safety, Durability, and Reduced Reinterventions with FLEX™ Vessel Prep System

Peripheral/Endo by 0 comments

LONDON, April 23, 2026 /PRNewswire/ — Minneapolis-based FLEX Vascular announced the presentation of 12-month results from the FLEX FIRST AV Registry, a prospective, multi-center, real-world study evaluating the FLEX™ Vessel Prep System in patients with dysfunctional hemodialysis access….

Continue Reading →
1 2 3 4 5 … 1,329